Pekin Hardy Strauss Inc. Takes Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

Pekin Hardy Strauss Inc. acquired a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 54,050 shares of the company’s stock, valued at approximately $571,000.

Several other hedge funds also recently modified their holdings of ROIV. Rubric Capital Management LP grew its holdings in shares of Roivant Sciences by 81.0% in the 4th quarter. Rubric Capital Management LP now owns 19,000,000 shares of the company’s stock valued at $213,370,000 after acquiring an additional 8,500,000 shares in the last quarter. Norges Bank bought a new position in Roivant Sciences during the fourth quarter worth about $41,506,000. First Trust Advisors LP grew its holdings in Roivant Sciences by 434.8% during the fourth quarter. First Trust Advisors LP now owns 2,739,438 shares of the company’s stock worth $30,764,000 after purchasing an additional 2,227,192 shares during the period. Penn Davis Mcfarland Inc. bought a new position in Roivant Sciences during the first quarter worth about $17,287,000. Finally, BlackBarn Capital Partners LP bought a new position in Roivant Sciences during the fourth quarter worth about $17,406,000. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Stock Up 0.1 %

NASDAQ ROIV opened at $12.05 on Wednesday. The company has a current ratio of 27.91, a quick ratio of 27.91 and a debt-to-equity ratio of 0.05. Roivant Sciences Ltd. has a 1-year low of $8.24 and a 1-year high of $13.24. The company has a 50 day moving average of $11.42 and a 200-day moving average of $11.04. The company has a market cap of $8.90 billion, a price-to-earnings ratio of 2.38 and a beta of 1.25.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.33. Roivant Sciences had a net margin of 2,991.75% and a negative return on equity of 17.23%. The company had revenue of $55.10 million during the quarter, compared to the consensus estimate of $30.72 million. During the same period in the previous year, the business earned ($0.38) earnings per share. The firm’s quarterly revenue was up 155.1% on a year-over-year basis. On average, equities research analysts expect that Roivant Sciences Ltd. will post -1.14 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ROIV. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a report on Wednesday, September 11th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Roivant Sciences in a report on Monday, September 9th. Piper Sandler lifted their price target on Roivant Sciences from $20.00 to $22.00 and gave the stock an “overweight” rating in a report on Wednesday, July 10th. Finally, Bank of America lifted their price target on Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a report on Wednesday, September 11th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, Roivant Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.15.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.